Clinical Trial

Adipose Stem Cell Mitochondria Supplementation to Oocytes (ASCENT)

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 17, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the potential of autologous adipose stem cell (ASC) mitochondrial transfer (ASCENT) to oocytes along with intracytoplasmic sperm injection (ICSI)as a means of enhancing embryo development and improving the success rate of in patients with a history of multiple IVF failures. Embryo quality plays a crucial role in determining the success of assisted reproductive technologies and directly contributes to repeated pregnancy failures. Several factors, including age, physiological conditions, genetics, and environmental influences, can significantly impact embryo quality. Oocytes, the largest cells in the human body, are heavily reliant on mitochondria. Mitochondria's role in providing energy for oocytes is crucial, and insufficient energy production has been linked to poor oocyte and embryo quality. Some human studies have shown that increasing oocyte mitochondrial mass can improve embryo quality in patients who have experienced repeated IVF failures.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-04.
Trial Details
NCT Number NCT07066267
Lead Sponsor Sunkaky Medical Cooperation
Collaborators: Wish Fertility Hospital Pvt. Ltd
Conditions Female Infertility, Oocyte Competence, Mitochondria, Recurent Implantation Failures, Advanced Age
Enrollment 20 participants
Start Date 2025-04-25
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-17